title: Benign prostate hyperplasia: evaluation of treatment response with DCE MRI.
abstract: Benign prostate hyperplasia (BPH) is a major disease and its non-surgical therapy a major area of interest. The purpose of this study was to establish perfusion parameters in beagles with BPH using dynamic contrast-enhanced (DCE) MRI and to investigate changes due to the effects of finasteride treatment. Twelve male beagles (mean age 4.4 +/- 0.9,years) were divided into a control and treatment group that received a daily dose of 1 mg/kg finasteride. DCE MRI was carried out in a clinical scanner using a 3D spoiled gradient echo sequence prior to and during treatment. 0.2 mmol/kg contrast agent (gadoteridol) was administered with an injection rate of 0.2 ml/s followed by a 15 ml flush of saline. Contrast enhancement was evaluated by pharmacokinetic mapping of a two-compartment model with colour overlay images in addition to regional ROI analysis. Quantitative parameters were defined by the amplitude of contrast enhancement A, the exchange rate k(ep) and the time to maximum signal enhancement. Dynamic contrast-enhanced MRI investigations of the prostate revealed two distinct zones, an inner, periurethral zone and an outer, parenchymal zone. The periurethral zone is highly vascularized, whereas the parenchymal zone is moderately vascularized when compared to other parenchymal organs. During treatment, in the parenchymal zone the intensity of enhancement (amplitude A) and the time to maximum signal enhancement increased, while the exchange rate k(ep) decreased. Dynamic contrast-enhanced MRI of BPH reveals distinct differences between individual zones within the prostate. Moreover, changes during successful treatment suggest increased blood volume per volume of tissue and decreased vessel leakiness.
authors.affiliation: The Ohio State University, Department of Radiology, 1654, Upham Drive, 647, Means Hall, Columbus, OH 43210-250, USA. heverhagen.1@osu.edu.
authors.forename: J T
authors.initials: JT
authors.lastname: Heverhagen
authors.forename: H
authors.initials: H
authors.lastname: von Tengg-Kobligk
authors.forename: K T
authors.initials: KT
authors.lastname: Baudendistel
authors.forename: G
authors.initials: G
authors.lastname: Jia
authors.forename: H
authors.initials: H
authors.lastname: Polzer
authors.forename: H
authors.initials: H
authors.lastname: Henry
authors.forename: A L
authors.initials: AL
authors.lastname: Levine
authors.forename: T J
authors.initials: TJ
authors.lastname: Rosol
authors.forename: M V
authors.initials: MV
authors.lastname: Knopp
mesh_terms: D000818:Animals; D003287:Contrast Media / Q000494:pharmacology; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018120:Finasteride / Q000494:pharmacology; D005682:Gadolinium; D006571:Heterocyclic Compounds / Q000494:pharmacology; D007700:Kinetics; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009942:Organometallic Compounds / Q000494:pharmacology; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D004791:Enzyme Inhibitors; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D018120:Finasteride; D005682:Gadolinium